Based out of London, Leucid Bio is a pioneering biotech company working on next-generation cell therapies for hard-to-treat cancers. Recently, the company announced that it secured £11.5 million in a Series A funding round.
Eyes Phase 1 trial
The investment was led by Epidarex and new investor Vulpes Investment Management. Also, other new investors 2Invest and Future Fund of the British Business Bank and current investor Sofinnova Partners participated in the round.
Leucid Bio will use the proceeds of this round to initiate a Phase 1 trial of its lead candidate – LEU-011, which will assist in the treatment of platinum-resistant ovarian cancer. The LEU-011 programme is an NKG2D CAR T-cell therapy in pre-clinical development for the treatment of solid tumours and haematological malignancies.
The NKG2D receptor is an activating immune receptor that triggers cell death upon recognition of human NKG2D ligands expressed on transformed, infected or…